Jasper Therapeutics (NASDAQ:JSPR) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Jasper Therapeutics (NASDAQ:JSPR) from a hold rating to a sell rating in a report published on Saturday morning.

Several other research firms have also recently commented on JSPR. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Piper Sandler began coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price target for the company. Finally, Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.17.

Jasper Therapeutics Stock Up 6.6%

JSPR stock opened at $0.84 on Friday. The stock has a market capitalization of $23.58 million, a price-to-earnings ratio of -0.53 and a beta of 3.02. Jasper Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.13. The stock’s fifty day simple moving average is $0.60 and its 200-day simple moving average is $0.90.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, analysts anticipate that Jasper Therapeutics will post -1.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Knott David M Jr grew its stake in Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after purchasing an additional 10,000 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics in the 1st quarter valued at approximately $46,000. Engineers Gate Manager LP acquired a new position in shares of Jasper Therapeutics in the 2nd quarter valued at approximately $78,000. Renaissance Technologies LLC boosted its stake in shares of Jasper Therapeutics by 9.0% during the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after buying an additional 18,683 shares during the last quarter. Finally, Panagora Asset Management Inc. purchased a new position in shares of Jasper Therapeutics during the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.